# Vaccitech plc (VACC)

Source: https://www.quantisnow.com/company/VACC
Generated: 2026-11-14T10:35:25.721Z

- Ticker: VACC
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2021
- Website: https://www.vaccitech.co.uk

## About

Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.

## Latest VACC news and filings

- 2024-02-13 15:17 UTC [SEC Schedule 13G] [SEC Form SC 13G/A filed by Vaccitech plc (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13ga-filed-by-vaccitech-plc-amendment-5253202)
- 2024-01-05 21:15 UTC [SEC Form 8-K] [Vaccitech plc filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/vaccitech-plc-filed-sec-form-8-k-results-of-operations-and-5173253)
- 2024-01-04 13:56 UTC [SEC Form 4] [SEC Form 4 filed by Pelletier Nadege](https://www.quantisnow.com/insight/sec-form-4-filed-by-pelletier-nadege-5168288)
- 2024-01-04 13:55 UTC [SEC Form 4] [SEC Form 4 filed by Griffiths Graham](https://www.quantisnow.com/insight/sec-form-4-filed-by-griffiths-graham-5168282)
- 2024-01-04 13:54 UTC [SEC Form 4] [SEC Form 4 filed by Enright William](https://www.quantisnow.com/insight/sec-form-4-filed-by-enright-william-5168272)
- 2024-01-04 13:52 UTC [SEC Form 4] [SEC Form 4 filed by Brown Gemma](https://www.quantisnow.com/insight/sec-form-4-filed-by-brown-gemma-5168265)
- 2023-12-22 21:01 UTC [SEC Form 8-K] [Vaccitech plc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/vaccitech-plc-filed-sec-form-8-k-entry-into-a-material-5153147)
- 2023-11-09 21:32 UTC [SEC Form 8-K] [Vaccitech plc filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/vaccitech-plc-filed-sec-form-8-k-regulation-fd-disclosure-other-5075643)
- 2023-11-09 21:18 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Vaccitech plc](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-vaccitech-plc-5075279)
- 2023-11-09 21:10 UTC [SEC Form 8-K] [Vaccitech plc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/vaccitech-plc-filed-sec-form-8-k-results-of-operations-and-5074997)
- 2023-11-06 16:04 UTC [SEC Form 8-K] [Vaccitech plc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/vaccitech-plc-filed-sec-form-8-k-submission-of-matters-to-5061412)
- 2023-11-06 14:08 UTC [Market Chatter] [Vaccitech Renames As Barinthus Biotherapeutics To Highlight Strategic Evolution Into A T Cell Immunotherapy Company Targeting Chronic Infectious Diseases, Autoimmunity, And Cancer; To Trade Under New Name And Ticker 'BRNS' Effective Nov. 7](https://www.quantisnow.com/insight/vaccitech-renames-as-barinthus-biotherapeutics-to-highlight-strategic-evolution-into-5061124)
- 2023-11-06 14:05 UTC [Vaccitech Renames as Barinthus Biotherapeutics to Highlight Strategic Evolution into a T Cell Immunotherapy Company Targeting Chronic Infectious Diseases, Autoimmunity, and Cancer](https://www.quantisnow.com/insight/vaccitech-renames-as-barinthus-biotherapeutics-to-highlight-strategic-evolution-into-5061112)
- 2023-10-31 21:31 UTC [Market Insight] [12 Health Care Stocks Moving In Tuesday's After-Market Session](https://www.quantisnow.com/insight/12-health-care-stocks-moving-in-tuesdays-after-market-session-5048018)
- 2023-10-05 20:05 UTC [SEC Form DEF 14A] [SEC Form DEF 14A filed by Vaccitech plc](https://www.quantisnow.com/insight/sec-form-def-14a-filed-by-vaccitech-plc-5007273)
- 2023-09-26 17:31 UTC [Market Insight] [12 Health Care Stocks Moving In Tuesday's Intraday Session](https://www.quantisnow.com/insight/12-health-care-stocks-moving-in-tuesdays-intraday-session-4988294)
- 2023-09-26 13:06 UTC [Market Insight] [12 Health Care Stocks Moving In Tuesday's Pre-Market Session](https://www.quantisnow.com/insight/12-health-care-stocks-moving-in-tuesdays-pre-market-session-4987830)
- 2023-09-25 21:19 UTC [SEC Form PRE 14A] [SEC Form PRE 14A filed by Vaccitech plc](https://www.quantisnow.com/insight/sec-form-pre-14a-filed-by-vaccitech-plc-4986832)
- 2023-09-25 17:31 UTC [Market Insight] [12 Health Care Stocks Moving In Monday's Intraday Session](https://www.quantisnow.com/insight/12-health-care-stocks-moving-in-mondays-intraday-session-4986267)
- 2023-09-25 16:36 UTC [Market Chatter] [Vaccitech Shares Resume Trade](https://www.quantisnow.com/insight/vaccitech-shares-resume-trade-4986215)
- 2023-09-25 16:32 UTC [Market Chatter] [Vaccitech Shares Halted On Circuit Breaker To The Upside, Stock Now Up 116.1%](https://www.quantisnow.com/insight/vaccitech-shares-halted-on-circuit-breaker-to-the-upside-stock-4986211)
- 2023-09-25 15:00 UTC [Market Insight] [Benzinga's Top Ratings Upgrades, Downgrades For September 25, 2023](https://www.quantisnow.com/insight/benzingas-top-ratings-upgrades-downgrades-for-september-25-2023-4986062)
- 2023-09-25 14:43 UTC [Market Chatter] [Vaccitech shares are trading higher after Alliance Global Partners initiated a Buy rating on the stock and announced a $12 price target.](https://www.quantisnow.com/insight/vaccitech-shares-are-trading-higher-after-alliance-global-partners-initiated-4986014)
- 2023-09-25 13:23 UTC [Market Chatter] [Alliance Global Partners Initiates Coverage On Vaccitech with Buy Rating, Announces Price Target of $12](https://www.quantisnow.com/insight/alliance-global-partners-initiates-coverage-on-vaccitech-with-buy-rating-4985885)
- 2023-09-25 09:41 UTC [Market Chatter] [Morgan Stanley Downgrades Vaccitech to Equal-Weight, Lowers Price Target to $3.25](https://www.quantisnow.com/insight/morgan-stanley-downgrades-vaccitech-to-equal-weight-lowers-price-target-to-4985329)
- 2023-09-13 12:00 UTC [Conference Announcement] [Vaccitech to Host KOL Webinar on Seeking a Functional Cure for Chronic Hepatitis B on September 20, 2023](https://www.quantisnow.com/insight/vaccitech-to-host-kol-webinar-on-seeking-a-functional-cure-4967992)
- 2023-09-11 17:38 UTC [Market Insight] [Stocks That Hit 52-Week Lows On Monday](https://www.quantisnow.com/insight/stocks-that-hit-52-week-lows-on-monday-4963975)
- 2023-09-07 17:55 UTC [Market Insight] [Stocks That Hit 52-Week Lows On Thursday](https://www.quantisnow.com/insight/stocks-that-hit-52-week-lows-on-thursday-4959302)
- 2023-08-18 13:54 UTC [Market Chatter] [Morgan Stanley Maintains Overweight on Vaccitech, Lowers Price Target to $14](https://www.quantisnow.com/insight/morgan-stanley-maintains-overweight-on-vaccitech-lowers-price-target-to-4915567)
- 2023-08-10 12:47 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Vaccitech plc](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-vaccitech-plc-4875193)
- 2023-08-10 12:12 UTC [SEC Form 8-K] [Vaccitech plc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/vaccitech-plc-filed-sec-form-8-k-results-of-operations-and-4874855)
- 2023-08-10 12:13 UTC [Market Chatter] [Vaccitech Q2 EPS $(0.62) Misses $(0.55) Estimate, Sales $334.00K Miss $600.00K Estimate](https://www.quantisnow.com/insight/vaccitech-q2-eps-062-misses-055-estimate-sales-33400k-miss-4874854)
- 2023-08-10 12:00 UTC [Earnings] [Vaccitech Reports Second Quarter 2023 Financial Results and Recent Corporate Developments](https://www.quantisnow.com/insight/vaccitech-reports-second-quarter-2023-financial-results-and-recent-corporate-4874638)
- 2023-07-26 20:06 UTC [SEC Form 8-K] [Vaccitech plc filed SEC Form 8-K: Leadership Update](https://www.quantisnow.com/insight/vaccitech-plc-filed-sec-form-8-k-leadership-update-4799653)
- 2023-07-04 21:37 UTC [Market Insight] [12 Health Care Stocks Moving In Tuesday's After-Market Session](https://www.quantisnow.com/insight/12-health-care-stocks-moving-in-tuesdays-after-market-session-4716688)
- 2023-06-28 11:52 UTC [SEC Form 4] [SEC Form 4 filed by Scheeren Joseph](https://www.quantisnow.com/insight/sec-form-4-filed-by-scheeren-joseph-4694133)
- 2023-06-21 20:05 UTC [SEC Form 8-K] [Vaccitech plc filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/vaccitech-plc-filed-sec-form-8-k-regulation-fd-disclosure-other-4668086)
- 2023-06-21 13:05 UTC [Market Insight] [Vaccitech To Present Final Data At EASL Congress For Phase 1b/2 HBV002 Study In Adults With Chronic Hepatitis B](https://www.quantisnow.com/insight/vaccitech-to-present-final-data-at-easl-congress-for-phase-4665589)
- 2023-06-21 13:03 UTC [Vaccitech to Present Positive Final Data at EASL Congress for Phase 1b/2 HBV002 Study in Adults with Chronic Hepatitis B](https://www.quantisnow.com/insight/vaccitech-to-present-positive-final-data-at-easl-congress-for-4665559)
- 2023-06-21 11:33 UTC [Market Chatter] [Arbutus Biopharma Has Dosed The First Patient In The Additional Treatment Arm Of The AB-729 Phase 2a Triple Combination Clinical Trial That Has Been Expanded To Include A Pd-1 Monoclonal Antibody, Opdivo (Nivolumab)](https://www.quantisnow.com/insight/arbutus-biopharma-has-dosed-the-first-patient-in-the-additional-4664568)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/VACC
- Earnings history: https://www.quantisnow.com/earnings/VACC
- Dividend history: https://www.quantisnow.com/dividends/VACC
- Insider transactions: https://www.quantisnow.com/insiders/VACC
- Options chain: https://www.quantisnow.com/options/VACC
- SEC 8-K filings only: https://www.quantisnow.com/company/VACC/8-k
- RSS and alerts for VACC: https://www.quantisnow.com/docs/rss-feeds.md